PMID- 24781637
OWN - NLM
STAT- MEDLINE
DCOM- 20150416
LR  - 20220331
IS  - 1573-2592 (Electronic)
IS  - 0271-9142 (Linking)
VI  - 34 Suppl 1
DP  - 2014 Jul
TI  - Immunomodulation and AD--down but not out.
PG  - S70-3
LID - 10.1007/s10875-014-0039-y [doi]
AB  - Alzheimer's disease (AD) is a progressive neurodegenerative disorder and is the 
      most common cause of dementia in the elderly. Interventions that remove existing 
      fibrillar and oligomeric amyloid-beta (Abeta) are believed to be essential for the 
      success of any attempt at stabilization of brain function and mitigation of 
      cognitive decline. Many of these strategies have focused on Abeta vaccination and 
      administration of anti-Abeta antibodies. Both active and passive immunotherapies 
      have been successful in mouse models, but both have had limited effect in 
      clinical trials. Intravenous immunoglobulin (IVIG) has been proposed as a 
      potential treatment for AD following evidence for behavioral benefit in AD models 
      and cognitive benefit in early phase 1 and phase 2 clinical trials. A phase 3 
      trial IVIG trial failed to meet its primary outcomes. While there was a 
      statistically significant benefit in moderate stage AD patients who carried an 
      APOE epsilon4 allele, this stabilization of cognition was evident only on 
      neuropsychological examination. No benefit on activities of daily living was 
      evident, therefore failing to qualify AD as a new indication for IVIG. 
      Identifying the biologically active component (s) responsible for the 
      neuropsychological benefit in APOE epsilon4-positive AD patients could enable the 
      development of a compound with greater potency that would qualify for FDA (US 
      Food and Drug Administration) registration.
FAU - Knight, E M
AU  - Knight EM
AD  - Departments of Neurology and Psychiatry and Alzheimer's Disease Research Center, 
      Icahn School of Medicine at Mount Sinai, New York, 10029, USA, 
      elysse.knight@mssm.edu.
FAU - Gandy, S
AU  - Gandy S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20140430
PL  - Netherlands
TA  - J Clin Immunol
JT  - Journal of clinical immunology
JID - 8102137
RN  - 0 (Alzheimer Vaccines)
RN  - 0 (Amyloid beta-Peptides)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Apolipoprotein E4)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Aged
MH  - Alzheimer Disease/genetics/immunology/*therapy
MH  - *Alzheimer Vaccines
MH  - Amyloid beta-Peptides/genetics/immunology/*metabolism
MH  - Animals
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Apolipoprotein E4/genetics
MH  - Clinical Trials as Topic
MH  - Cognition/drug effects
MH  - Disease Models, Animal
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Immunomodulation
MH  - Mice
MH  - Proteolysis/drug effects
EDAT- 2014/05/02 06:00
MHDA- 2015/04/17 06:00
CRDT- 2014/05/01 06:00
PHST- 2014/03/31 00:00 [received]
PHST- 2014/04/02 00:00 [accepted]
PHST- 2014/05/01 06:00 [entrez]
PHST- 2014/05/02 06:00 [pubmed]
PHST- 2015/04/17 06:00 [medline]
AID - 10.1007/s10875-014-0039-y [doi]
PST - ppublish
SO  - J Clin Immunol. 2014 Jul;34 Suppl 1:S70-3. doi: 10.1007/s10875-014-0039-y. Epub 
      2014 Apr 30.